Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Jens Kuhle, Harald Kropshofer, Dieter A Haering, Uma Kundu, Rolf Meinert, Christian Barro, Frank Dahlke, Davorka Tomic, David Leppert, Ludwig Kappos, Jens Kuhle, Harald Kropshofer, Dieter A Haering, Uma Kundu, Rolf Meinert, Christian Barro, Frank Dahlke, Davorka Tomic, David Leppert, Ludwig Kappos

Abstract

Objective: To assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis.

Methods: We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes.

Results: At baseline, NfL levels (pg/mL) were higher in patients than in healthy controls (30.5 and 27.0 vs 16.9, p = 0.0001) and correlated with T2 lesion load and number of gadolinium-enhancing T1 lesions (p < 0.0001, both). Baseline NfL levels, treatment, and number of new or enlarging T2 lesions during the studies predicted NfL levels at the end of study (all p < 0.01). High vs low baseline NfL levels were associated (estimate [95% confidence interval]) with an increased number of new or enlarging T2 lesions (ratio of mean: 2.64 [1.51-4.60]; p = 0.0006), relapses (rate ratio: 2.53 [1.67-3.83]; p < 0.0001), brain volume loss (difference in means: -0.78% [-1.02 to -0.54]; p < 0.0001), and risk of confirmed disability worsening (hazard ratio: 1.94 [0.97-3.87]; p = 0.0605). Fingolimod significantly reduced NfL levels already at 6 months (vs placebo 0.73 [0.656-0.813] and IFN 0.789 [0.704-0.884]), which was sustained until the end of the studies (vs placebo 0.628 [0.552-0.714] and IFN 0.794 [0.705-0.894]; p < 0.001, both studies at all assessments).

Conclusions: Blood NfL levels are associated with clinical and MRI-related measures of disease activity and neuroaxonal damage and have prognostic value. Our results support the utility of blood NfL as an easily accessible biomarker of disease evolution and treatment response.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Baseline NfL concentrations in patients…
Figure 1. Baseline NfL concentrations in patients with relapsing-remitting multiple sclerosis and healthy controls
The box represents the interquartile range, with the median represented by the line in the center; n = number of patients with evaluable data. The black dot represents the GeoMean value and the whiskers indicate the 10th and 90th percentiles. Dotted line represents plasma NfL (pg/mL, median) concentrations in healthy controls. The p Values are based on a Wilcoxon rank sum test. GeoMean = geometric mean; Max = maximum; Min = minimum; NfL = neurofilament light chain.
Figure 2. Blood NfL levels by T2…
Figure 2. Blood NfL levels by T2 lesion volume (mm3) at baseline: (A) FREEDOMS, (B) TRANSFORMS
The box represents the interquartile range, with the median represented by the line in the center; n = number of patients with evaluable data. The black dot represents the geometric mean value and the whiskers indicate the 10th and 90th percentiles. Dotted line represents plasma NfL (pg/mL, median) concentrations in healthy controls. NfL = neurofilament light chain.
Figure 3. Blood NfL levels by Gd+…
Figure 3. Blood NfL levels by Gd+ T1 lesion count at baseline: (A) FREEDOMS, (B) TRANSFORMS
The box represents the interquartile range, with the median represented by the line in the center; n = number of patients with evaluable data. The black dot represents the geometric mean value and the whiskers indicate the 10th and 90th percentiles. Dotted line represents plasma NfL (pg/mL, median) concentrations in healthy controls. Gd+ = gadolinium-enhancing; NfL = neurofilament light chain.
Figure 4. Effect of fingolimod on NfL…
Figure 4. Effect of fingolimod on NfL levels in blood, (A) compared with placebo, FREEDOMS study; (B) compared with interferon-β-1a, TRANSFORMS study
The figure shows geometric means of NfL with 95% confidence intervals and statistical tests from mixed models for repeated measurements of postbaseline NfL. Dotted line represents plasma NfL (pg/mL, geometric mean) concentrations in healthy controls. ***p < 0.0001. n = number of patients with evaluable data. NfL = neurofilament light chain.

References

    1. Wattjes MP, Rovira À, Miller D, et al. . Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606.
    1. Saindane AM, Law M, Ge Y, Johnson G, Babb JS, Grossman RI. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol 2007;28:767–772.
    1. Arrambide G, Espejo C, Eixarch H, et al. . Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016;87:1076–1084.
    1. Kuhle J, Barro C, Disanto G, et al. . Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016;22:1550–1559.
    1. Kuhle J, Nourbakhsh B, Grant D, et al. . Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017;88:826–831.
    1. Disanto G, Barro C, Benkert P, et al. . Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857–870.
    1. Piehl F, Kockum I, Khademi M, et al. . Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 2018;24:1046–1054.
    1. Novakova L, Zetterberg H, Sundström P, et al. . Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 2017;89:2230–2237.
    1. Barro C, Benkert P, Disanto G, et al. . Serum neurofilament light chain as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain Epub 2018 May 30.
    1. Gisslen M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NfL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 2016;3:135–140.
    1. Kappos L, Radue EW, O'Connor P, et al. . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401.
    1. Cohen JA, Barkhof F, Comi G, et al. . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–415.
    1. De Stefano N, Silva DG, Barnett MH. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs 2017;31:289–305.
    1. Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;63:1586–1590.
    1. Teunissen CE, Iacobaeus E, Khademi M, et al. . Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322–1329.
    1. Gunnarsson M, Malmeström C, Axelsson M, et al. . Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83–89.
    1. Romme Christensen J, Börnsen L, Khademi M, et al. . CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2013;19:877–884.
    1. Novakova L, Axelsson M, Khademi M, et al. . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 2017;141:296–304.
    1. Kappos L, Moeri D, Radue EW, et al. . Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964–969.
    1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–245.
    1. Radue EW, Barkhof F, Kappos L, et al. . Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 2015;84:784–793.
    1. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202–2212.
    1. Petzold A, Steenwijk MD, Eikelenboom JM, Wattjes MP, Uitdehaag BM. Elevated CSF neurofilament proteins predict brain atrophy: a 15-year follow-up study. Mult Scler 2016;22:1154–1162.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever